| Synthesis of N1-arylidene-N2-quinolyl-and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains S Gemma, G Kukreja, C Fattorusso, M Persico, MP Romano, M Altarelli, ... Bioorganic & medicinal chemistry letters 16 (20), 5384-5388, 2006 | 254 | 2006 |
| Multitarget compounds bearing tacrine-and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease L Ismaili, B Refouvelet, M Benchekroun, S Brogi, M Brindisi, S Gemma, ... Progress in neurobiology 151, 4-34, 2017 | 199 | 2017 |
| Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors L Savini, A Gaeta, C Fattorusso, B Catalanotti, G Campiani, L Chiasserini, ... Journal of Medicinal Chemistry 46 (1), 1-4, 2003 | 187 | 2003 |
| Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77 C Ferlini, L Cicchillitti, G Raspaglio, S Bartollino, S Cimitan, C Bertucci, ... Cancer research 69 (17), 6906-6914, 2009 | 184 | 2009 |
| Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives G Campiani, A Ramunno, G Maga, V Nacci, C Fattorusso, B Catalanotti, ... Current pharmaceutical design 8 (8), 615-657, 2002 | 163 | 2002 |
| Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT3 Receptor Agonists: Synthesis, Further Structure−Activity Relationships, and Biological Studies G Campiani, E Morelli, S Gemma, V Nacci, S Butini, M Hamon, ... Journal of medicinal chemistry 42 (21), 4362-4379, 1999 | 143 | 1999 |
| The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance C Ferlini, G Raspaglio, S Mozzetti, L Cicchillitti, F Filippetti, D Gallo, ... Cancer research 65 (6), 2397-2405, 2005 | 135 | 2005 |
| Identification of a more potent analogue of the naturally occurring alkaloid huperzine A. Predictive molecular modeling of its interaction with AChE AP Kozikowski, G Campiani, LQ Sun, S Wang, A Saxena, BP Doctor Journal of the American Chemical Society 118 (46), 11357-11362, 1996 | 134 | 1996 |
| Thiazolothiazepine inhibitors of HIV-1 integrase N Neamati, JA Turpin, HE Winslow, JL Christensen, K Williamson, A Orr, ... Journal of Medicinal Chemistry 42 (17), 3334-3341, 1999 | 127 | 1999 |
| A palladium-catalyzed route to huperzine A and its analogs and their anticholinesterase activity G Campiani, LQ Sun, AP Kozikowski, P Aagaard, M McKinney The Journal of Organic Chemistry 58 (27), 7660-7669, 1993 | 126 | 1993 |
| Caspase‐3 is not essential for DNA fragmentation in MCF‐7 cells during apoptosis induced by the pyrrolo‐1, 5‐benzoxazepine, PBOX‐6 MM Mc Gee, E Hyland, G Campiani, A Ramunno, V Nacci, DM Zisterer FEBS letters 515 (1-3), 66-70, 2002 | 124 | 2002 |
| Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally … G Campiani, F Aiello, M Fabbrini, E Morelli, A Ramunno, S Armaroli, ... Journal of medicinal chemistry 44 (3), 305-315, 2001 | 123 | 2001 |
| Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific “peripheral-type” benzodiazepine receptor ligands G Campiani, V Nacci, I Fiorini, MP De Filippis, A Garofalo, SM Ciani, ... Journal of medicinal chemistry 39 (18), 3435-3450, 1996 | 118 | 1996 |
| Synthesis and Pharmacological Evaluation of Potent and Highly Selective D3 Receptor Ligands: Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D3/D … G Campiani, S Butini, F Trotta, C Fattorusso, B Catalanotti, F Aiello, ... Journal of medicinal chemistry 46 (18), 3822-3839, 2003 | 115 | 2003 |
| Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases M Brindisi, AP Saraswati, S Brogi, S Gemma, S Butini, G Campiani Journal of medicinal chemistry 63 (1), 23-39, 2019 | 103 | 2019 |
| Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases S Maramai, S Gemma, S Brogi, G Campiani, S Butini, H Stark, M Brindisi Frontiers in neuroscience 10, 451, 2016 | 103 | 2016 |
| Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors … S Butini, S Gemma, G Campiani, S Franceschini, F Trotta, M Borriello, ... Journal of medicinal chemistry 52 (1), 151-169, 2009 | 103 | 2009 |
| Design, synthesis, and structure–activity relationship studies of 4-quinolinyl-and 9-acrydinylhydrazones as potent antimalarial agents C Fattorusso, G Campiani, G Kukreja, M Persico, S Butini, MP Romano, ... Journal of medicinal chemistry 51 (5), 1333-1343, 2008 | 100 | 2008 |
| Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663 G Maga, S Gemma, C Fattorusso, GA Locatelli, S Butini, M Persico, ... Biochemistry 44 (28), 9637-9644, 2005 | 99 | 2005 |
| Modulation of the innate immune response by targeting toll-like receptors: a perspective on their agonists and antagonists S Federico, L Pozzetti, A Papa, G Carullo, S Gemma, S Butini, ... Journal of Medicinal Chemistry 63 (22), 13466-13513, 2020 | 98 | 2020 |
